Dmitry Derkach

Dmitry Derkach is a founding member of bioSyntagma with a background in Molecular and Cellular Biology as well as clinical practice as an MD. Dr. Derkach has almost 20-years lab and industrial experience in drug/bioassay development, validation and implementation. Dr. Derkach practiced medicine for 4 years in the ICU before advancing to achieve his PhD in Molecular Biology at Kyushu University (Japan) and postdoctoral work at University of Arizona. He moved to a pharmaceutical company in Phoenix, AZ where he developed two cell based potency assays and elucidated mechanisms of action for two peptide based drugs. His 5-years in FDA regulated lab work was focused on developing peptide-based drugs for use in the US market. In 2013 Dr. Derkach joined the Biodesign Institute developing novel, high-throughput genomic screening tools.